← All Advanced Biomed INC filings

Advanced Biomed INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
ADVB
Advanced Biomed INC
10-Q: Advanced Biomed Inc. Q3 2026 Earnings: Strategic Pivot and Financial Review
Advanced Biomed Inc. reports a net income of $5.98 million for the nine months ended March 31, 2026, driven by a significant gain from subsidiary disposal, alongside increased R&D spending and a strategic shift towards AI.
NASDAQ
ADVB
Advanced Biomed INC
10-Q: Advanced Biomed Reports Wider Q3 Loss, Going Concern Doubt
Advanced Biomed Inc. reported a significantly wider net loss and increased cash burn from operations for the quarter ended September 30, 2025, raising substantial doubt about its ability to continue as a going concern.
NASDAQ
ADVB
Advanced Biomed INC
10-Q: Advanced Biomed Inc. Reports Q3 2025 Results, Highlights IPO and Ongoing R&D
Advanced Biomed Inc. reports its Q3 2025 results, highlighting its recent IPO and ongoing research and development efforts in microfluidic biochip technology for oncology.
NASDAQ
ADVB
Advanced Biomed INC
10-Q: Advanced Biomed Inc. Reports Net Loss in Q2 2025, Cites Ongoing R&D and Regulatory Processes
Advanced Biomed Inc. reports a net loss for the quarter ended December 31, 2024, as it continues to invest in research and development and navigate regulatory approvals for its cancer detection and diagnosis technologies.